Press Release March 13, 2022Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin 0 0 Share
Press Release March 4, 2022Core One Labs' Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations 0 0 Share
Press Release February 10, 2022Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT 0 0 Share
Press Release January 9, 2022Core One Labs Now Also Working to Biosynthesize DMT and Receives License 0 0 Share
Press Release July 18, 2021Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021 0 0 Share
Press Release June 22, 2021REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed 0 0 Share
Press Release June 20, 2021New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed 0 0 Share
Press Release June 18, 2021Core One Labs Retains Canada's Highest-Ranked IP Law Firm to Assist With Patent Filings 0 0 Share
